- Home
- CCD vs ABVX Comparison
CCD vs ABVX Comparison
Compare CCD & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCD
- ABVX
- Stock Information
- Founded
- CCD 2014
- ABVX 2013
- Country
- CCD United States
- ABVX France
- Employees
- CCD N/A
- ABVX N/A
- Industry
- CCD Trusts Except Educational Religious and Charitable
- ABVX
- Sector
- CCD Finance
- ABVX
- Exchange
- CCD Nasdaq
- ABVX Nasdaq
- Market Cap
- CCD 656.6M
- ABVX 722.3M
- IPO Year
- CCD N/A
- ABVX N/A
- Fundamental
- Price
- CCD $24.04
- ABVX $8.08
- Analyst Decision
- CCD
- ABVX Strong Buy
- Analyst Count
- CCD 0
- ABVX 7
- Target Price
- CCD N/A
- ABVX $37.86
- AVG Volume (30 Days)
- CCD 96.1K
- ABVX 162.8K
- Earning Date
- CCD 01-01-0001
- ABVX 03-24-2025
- Dividend Yield
- CCD 10.61%
- ABVX N/A
- EPS Growth
- CCD N/A
- ABVX N/A
- EPS
- CCD N/A
- ABVX N/A
- Revenue
- CCD N/A
- ABVX $9,676,417.00
- Revenue This Year
- CCD N/A
- ABVX $31.67
- Revenue Next Year
- CCD N/A
- ABVX $759.77
- P/E Ratio
- CCD N/A
- ABVX N/A
- Revenue Growth
- CCD N/A
- ABVX 100.87
- 52 Week Low
- CCD $16.93
- ABVX $5.50
- 52 Week High
- CCD $24.68
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- CCD 40.27
- ABVX 75.42
- Support Level
- CCD $24.45
- ABVX $5.88
- Resistance Level
- CCD $24.73
- ABVX $7.57
- Average True Range (ATR)
- CCD 0.36
- ABVX 0.46
- MACD
- CCD -0.05
- ABVX 0.24
- Stochastic Oscillator
- CCD 9.57
- ABVX 97.68
About CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.